Skip to main content
Log in

Usefulness of polysaccharide K (PSK) as postoperative adjuvant immunotherapy in patients with stage IV gastric cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background. We investigated retrospectively the usefulness of polysaccharide K (PSK) administration for prolonging survival after noncurative resection in patients with stage IV gastric cancer who underwent surgery at our department.

Methods. 357 patients with gastric cancer evaluated as stage IV according to thegeneral rules for gastric cancer study, 11th edn (1985) of the Japanese Research Society for Gastric Cancer, who were expected to succumb to surgical death or postoperative death within 2 months were studied. The patients were divided into two groups: total PSK dosage greater than or less than 180g. Survival rates were calculated for each group.

Results. In these stage-IV gastric cancer patients, the 5-year and 10-year survival rates in the PSK group were both 13.9%. In the non-PSK group, the rates were 8.7% and 7.0%, respectively. The survival rates were significantly higher in the PSK group (p = 0.0001). The survival rate was also calculated with respect to the staging factors. Patients in the PSK group who had H0, P0, se or milder and n3 or n4 showed a significantly higher survival rate than those with these staging factors in the non-PSK group (p = 0.010).

Conclusion. PSK administration prolonged survival in stage-IV gastric cancer patients, the effect being marked in patients with severe lymph node metastasis. We suggest that be administered as adjuvant therapy in stage-IV gastric cancer patients with severe lymph node metastasis (n3, n4).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ohtsu A, Yoshida S, Miyata Y, Shimada Y (1995) Recent advances in chemotherapy for advance gastric cancer: From the standpoint of survival advantage. Jpn J Cancer Chemother 22:444–450

    CAS  Google Scholar 

  2. Iwanaga T, Hiratuka M, Furukawa H, et al. (1992) Extensive radical surgery and its result: Multi organ resection in the surgery of gastric cancer (in Japanese). Gekashinryo 34:55–62

    Google Scholar 

  3. Nakazato H, Koike A, Saji S, et al. (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122–1126

    Article  PubMed  CAS  Google Scholar 

  4. Japanese Research Society for Gastric Cancer (1985) The general rules for gastric cancer study, March 1985 11th edn (in Japanese). Kanehara, Tokyo

  5. Glasgow AH, Nimberg RB, Menzoian JO, et al. (1974) Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med 98:413–421

    Google Scholar 

  6. Nomoto K, Tsuru S, Awane Y, et al. (1986) Changes of nonspecific suppressor factors in the serum of gastric cancer patients after surgery and immunochemotherapy. Jpn J Cancer Chemother 13:458–463

    CAS  Google Scholar 

  7. Kondo Y, Uchino J, Sawaguchi Y, et al. (1996) Evalution of Multi Skin Test in colorectal cancer patients and effects of serum immunosuppressive factor and cytokine production of peripheral mononuclear cells. Am J Clin Oncol 19:159–163

    Article  PubMed  CAS  Google Scholar 

  8. Sekizuka H, Suguro K, Haruyama S, et al. (1985) Cellular immunity in postoperative patients of gastric cancer; the effect of immunomodulators (in Japanese). Jpn J Cancer Clin 31:1381–1386

    CAS  Google Scholar 

  9. Harada M, Matsunaga K, Oguchi Y, et al. (1995) The involvement of transforming growth factor β in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res 55:6146–6151

    PubMed  CAS  Google Scholar 

  10. Saji S, Sugiyama Y, Kunieda K (1994) Cyotokine response induced by surgical stress (in Japanese). Surgery Frontier 1:7–13

    Google Scholar 

  11. Hersh EM (1974) Immunosuppressive agents. In: Sartoli AC, Jhons DG (eds) Antineoplastics and immunosuppressive agents. I. Springer, New York, pp 577–617

    Google Scholar 

  12. Saji S, Kida T, Kunieda K, et al. (1985) Five-year survival of gastric cancer patients treated with postoperative long term adjuvant immunochemotherapy. Prog Med 5:485–492

    Google Scholar 

  13. Saji S, Takao H, Kida T, et al. (1987) Effects of postoperative adjuvant immunochemotherapy using PSK for patients of gastric cancer, and its preventive effects on the recurrence. Prog Med 8:1703–1709

    Google Scholar 

  14. Kabe S, Tamakuma M, Mimura K, et al. (1985) Controlled study in stage IV gastric cancer of adjuvant immunochemotherapy with chemotherapy (in Japanese). Jpn J Cancer Clin 31:1805–1809

    Google Scholar 

  15. Mitomi T, Ogoshi K (1986) Clinical Study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Jpn J Cancer Chemother 13:2532–2537

    CAS  Google Scholar 

  16. Vanky F, Wang P, Klein E (1992) The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumor cells. Cancer Immunol Immunother 35:193–198

    Article  PubMed  CAS  Google Scholar 

  17. Nio Y, Shiraishi T, Tsubono M, et al. (1991) In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32:335–341

    Article  PubMed  CAS  Google Scholar 

  18. Fujii M, Fujii T, Saito K, et al. (1987) Tumor growth promoting activity of an immunosuppressive substance and its modulation by protein-bound polysaccharide PSK. Immun Lett 15:347–351

    Article  CAS  Google Scholar 

  19. Hattori T, Nakajima T, Nakazato H, et al. (1990) Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg 20:127–136

    Article  PubMed  CAS  Google Scholar 

  20. Ebina T, Kohya H, Ishikawa K (1989) Antitumor effect of PSK: Role of regional lymph nodes and enhancement of concomitant and sinecomitant immunity in the mouse. Jpn J Cancer Res 80:158–166

    PubMed  CAS  Google Scholar 

  21. Okabayashi T, Horimi T, Gouchi A, et al. (1986) Immunohistochemical analysis of regional lymph nodes in gastric cancer (in Japanese). Jpn J Gastroenterol Surg 19:844–848

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Kuroda, Y., Horikawa, N., Tsuji, M. et al. Usefulness of polysaccharide K (PSK) as postoperative adjuvant immunotherapy in patients with stage IV gastric cancer. Int J Clin Oncol 3, 311–316 (1998). https://doi.org/10.1007/BF02628052

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02628052

Key words

Navigation